Robert Michael Dudley - Jun 20, 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role: Chief Executive Officer, Director
Signature: /s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Stock symbol: RNAZ
Transactions as of: Jun 20, 2023
Transactions value $: $48,665
Form type: 4
Date filed: 6/22/2023, 06:23 PM
Previous filing: Jun 14, 2023
Next filing: Oct 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNAZ	Common Stock	Purchase	$16.8K	+6.61K	+10.38%	$2.55	70.3K	Jun 20, 2023	Direct	F1
transaction	RNAZ	Common Stock	Purchase	$31.8K	+12K	+17.08%	$2.65	82.3K	Jun 21, 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
F2	Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.

Content

Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.

Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.